Please login to the form below
US market
This page shows the latest US market news and features for those working in and with pharma, biotech and healthcare.
Fishawack Health acquires market access and HEOR consultancy PRMA Consulting
Global healthcare communications company Fishawack Health has acquired global market access and health economics outcomes research (HEOR) consultancy PRMA Consulting. ... The acquisition adds to Fishawack a presence in the Asia-Pacific and Europe, where
Latest news
-
Servier to acquire Agios’ oncology business in $1.8bn deal
It is a key step for the Servier Group as it will significantly strengthen our position in the US and reinforce our R&D capabilities in oncology. ... Aside from strengthening its oncology portfolio, Servier’s acquisition of Agios will allow the company
-
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
Bringing Zepzelca to the US market earlier this year alongside our partner, PharmaMar, was an important advance for adults with metastatic SCLC, an aggressive disease with a historically poor prognosis," said ... Jazz licensed lurbinectedin from
-
AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
Researchers found that Venclyxto (venetoclax) – known as Venclexta in the US – in combination with azacitidine extended overall survival (OS) compared to the azacitidine plus placebo arm. ... 2020. AbbVie sells the drug on its own outside the US,
-
Novartis stumbles in Q2 as COVID-19 impacts sales
Our growth drivers and launches continue their strong momentum, with Cosentyx and Entresto increasing market share in the US.
-
EU grants approval for Venclyxto/Gazyvaro combo in CLL
CLL). Venclyxto (venetoclax) – known as Venclexta in the US – was co-developed by AbbVie and Roche and the combination with Gazyva (obinutuzumab) in frontline treatment of CLL could see its use ... AbbVie sells the drug on its own outside the US,
Servier to acquire Agios’ oncology business in $1.8bn deal
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
Novartis stumbles in Q2 as COVID-19 impacts sales
EU grants approval for Venclyxto/Gazyvaro combo in CLL
More from news
Approximately 1 fully matching, plus 824 partially matching documents found.
Latest Intelligence
-
Piloting a route to the biosimilars opportunities in Europe
By 2023, patents will expire for most formulations, creating a large potential market for biosimilars. ... The US market also has a lot of interest in creating cohesive guidelines and legislation around biosimilars interchangeability, something that is
-
Setting up for success in a post-Brexit, post-pandemic Britain
as new to the MHRA as it is to us and requirements are being updated weekly. ... I have no doubt that the UK market will enable us at Galapagos to continue to do pioneering work for patients in 2021 and beyond.
-
Growing evidence supports the important role of biosimilars in healthcare
Access to healthcare, including affordable medicines, remains a top concern across the US. ... As more biosimilars enter the US market, patients treated with biologic medicines will have access to a broader set of more affordable treatment options.
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Yet unlike generic medicines, which have delivered substantial savings in the small molecule market, the success of biosimilars in the US has been mixed. ... Moreover, increasing the number of available biosimilars on the US market can improve access to
-
Will biosimilars ever catch on in the US?
But for the most part, the feast-and-famine cycle of the US market has been viewed as a success. ... And finally there is the issue of interchangeability. In a move unique to the US market, the BPCI created two pathways for approval: an abbreviated one
Piloting a route to the biosimilars opportunities in Europe
Setting up for success in a post-Brexit, post-pandemic Britain
Growing evidence supports the important role of biosimilars in healthcare
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Will biosimilars ever catch on in the US?
More from intelligence
Approximately 0 fully matching, plus 54 partially matching documents found.
Latest appointments
-
New faces at 11 London, ramarketing and MSL
The new office in Cambridge, Massachusetts, will give ramarketing a presence in the growing pharma and biotech hub and a foothold in the US market, allowing it to locally service its ... Emma’s insight into the global life sciences sector means she
-
Pharma industry appointments
Prior to this, Jenkins spent 17 years at GlaxoSmithKline (GSK) in the UK and US. ... UK. Vu, whose new post will see him further expand Concept’s presence in the US market, joins the company with over 15 years’ experience in both business development
-
Open Health creates new role
Joining the agency with twenty years’ biopharmaceutical industry experience, Jones’ expertise lies in market access, therapy launch and patient centric services. ... Creating a unique role within our field of expertise will enable us to offer a
-
W2O bolsters its commercialisation offering
Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Joining the network from Edelman, Glaze previously led the design and implementation of its US market access communications offering.
-
Amra appoints new VP of North American sales Jeremy Edwards
With more than 20 years’ experience in the clinical development industry, Edwards joins the company after spending five years as vice president and general manager of the US operations for Exco ... expand the US market.”.
New faces at 11 London, ramarketing and MSL
Pharma industry appointments
Open Health creates new role
W2O bolsters its commercialisation offering
Amra appoints new VP of North American sales Jeremy Edwards
More from appointments
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest from PMHub
-
Lucid Group Evolve and Simplify its Brand Architecture
Lighthouse Medical Communications US (focusing on the US market) and Bluedog (digital and creative). ... Effective immediately, all teams delivering medical communications outside of the US will now fall under just one Lucid Group brand – aptly named,
-
Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering
Move builds on Envision’s established leadership position as the preferred tech-enabled scientific communications company for medical affairs, while deepening its presence in the critical US domestic market, and with ... With Envision’s global
-
Consumer health specialist joins Research Partnership Inc
Global healthcare market research consultancy Research Partnership has appointed Jennifer Stewart as a Director in their US offices in Philadelphia. ... Jennifer is a seasoned market research professional with extensive experience in both custom research
-
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up and we would love to work with you.
-
Top 5 tips for a multi-indication product launch
Today, it is more common to remain in ‘launch mode’ after the first entry into the market. ... Difficulties can arise when the US market represents the highest global sales and heavily influences the brand and creative strategy.
Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering
More from PMHub
Approximately 0 fully matching, plus 39 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
